within Pharmacolibrary.Drugs.ATC.M;

model M01AH07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.53,
    Cl             = 7.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0157,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 11.4
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AH07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Polmacoxib is a nonsteroidal anti-inflammatory drug (NSAID) with selective COX-2 inhibitory activity. It is approved in South Korea for the treatment of osteoarthritis and rheumatoid arthritis. Polmacoxib is unique in also inhibiting carbonic anhydrase, and is used for pain and inflammation management.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult Korean male volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Skarke, C, et al., &amp; Fitzgerald, GA (2012). Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. <i>Clinical pharmacology and therapeutics</i> 91(6) 986–993. DOI:<a href=\"https://doi.org/10.1038/clpt.2012.3\">10.1038/clpt.2012.3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22278334/\">https://pubmed.ncbi.nlm.nih.gov/22278334</a></p></li><li><p>Youn Choi, H, et al., &amp; Lim, HS (2014). Effects of ketoconazole on the pharmacokinetic properties of CG100649, a novel NSAID: a randomized, open-label crossover study in healthy Korean male volunteers. <i>Clinical therapeutics</i> 36(1) 115–125. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2013.12.004\">10.1016/j.clinthera.2013.12.004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24417786/\">https://pubmed.ncbi.nlm.nih.gov/24417786</a></p></li><li><p>Hirankarn, S, et al., &amp; Skarke, C (2013). GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies. <i>Clinical pharmacology in drug development</i> 2(4) 379–386. DOI:<a href=\"https://doi.org/10.1002/cpdd.47\">10.1002/cpdd.47</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27121942/\">https://pubmed.ncbi.nlm.nih.gov/27121942</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AH07;
